{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"52"}]}],"title":"Number of responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"51"}]}],"title":"Week 12 (Day 84); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Week 12 (Day 84); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"50"}]}],"title":"Week 24 (Day 168); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Week 24 (Day 168); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"35"}]}],"title":"Week 48 (Day 336); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Week 48 (Day 336); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"}]}],"title":"Week 72 (Day 504); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Week 72 (Day 504); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Week 96 (Day 672); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Week 96 (Day 672); With disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Week 120 (Day 840); Without disease progression"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"}]}],"title":"Week 120 (Day 840); With disease progression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Tumor Volume Score (TVS) is a semi-quantitative MRI scoring system that describes tumor mass and is based on 10% increments of the estimated volume of the maximally distended synovial cavity or tendon sheath involved. A tumor that is equal in volume to that of a maximally distended synovial cavity or tendon sheath was scored 10; a score of 0 indicated no evidence of tumor. The overall number of responses and the number of participants with and without disease progression was assessed.","groups":[{"description":"Participants received treatment of Pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks in Part 1 and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPexidartinib: Each capsule contains 200 mg of pexidartinib for oral administration","id":"OG000","title":"Pexidartinib in Part 1 and Part 2"},{"description":"Participants received treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks in Part 1 and also received Pexidartinib in Part 2 at their prescribed dose.\n\nPlacebo: Placebo capsule matching Pexidartinib capsule for oral administration Pexidartinib: Each capsule contains 200 mg of Pexidartinib for oral administration.","id":"OG001","title":"Placebo Part 1, Pexidartinib Part 2"},{"description":"All participants who received pexidartinib in Part 1 and Part 2 as well as those who received pexidartinib in Part 2 only.","id":"OG002","title":"All Pexidartinib Treated"}],"paramType":"NUMBER","populationDescription":"The overall number of responses and the number of participants with and without disease progression was assessed in the ITT population, specifically among the Pexidartinib Part 1, Pexidartinib Part 2; Pexidartinib Part 2 only; and All Pexidartinib Treated participants. Participants who received Placebo Part 1 only were not analyzed.","reportingStatus":"POSTED","timeFrame":"By Week 120","title":"Number of Responders to Pexidartinib With and Without Disease Progression Based on Tumor Volume Score","type":"SECONDARY","unitOfMeasure":"participants"}